Page 1731 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 96 Investigational New Drug–Enabling Processes for Cell-Based Therapies 1536.e1

REFERENCES 13. US Food and Drug Administration, Center for Drug Evaluation and
Research, Center for Biologics Evaluation and Research: Formal meetings
1. Title 21 Code of Federal Regulations: Part 211 Current good manufactur- between the FDA and sponsors or applicants of PDUFA products, March
ing practice for finished pharmaceuticals, April 2011. 2015.
2. Title 21 Code of Federal Regulations: Part 1271 Human cells, tissues, and 14. US Food and Drug Administration, Center for Biologics Evaluation and
cellular and tissue-based products May 25, 2005. Research: SOPP 8101.1—Scheduling and conduct of regulatory review
3. Burger S: GTP/GMP cell engineering for cell and gene therapies. meetings with sponsors and applicants, Version 5, October 15, 2012.
BioProcess J 2:1–4, 2003. 15. US Food and Drug Administration, Center for Biologics Evaluation and
4. Guidance for Industry: Potency tests for cellular and gene therapy products, Research Guidance for FDA Review Staff and Sponsors: Content and
January 2011. review of chemistry, manufacturing, and control (CMC) information for
5. US Pharmacopeia: <1046> General information chapter, cell and gene human gene therapy investigational new drug applications (INDs), April 9,
therapy products, United States, Rockville, MD, March 2002. 2008.
6. Guidance for Industry: Source Animal, Product, Preclinical, and Clinical 16. Title 21 Code of Federal Regulations: Part. 312.23, IND content and
Issues Concerning the Use of Xenotransplantation Products in Humans: Final format, 2005.
Guidance, April 2003. 17. US Food and Drug Administration, Center for Biologics Evaluation
7. Brandenberger R, et al: Integrating process and product development for the and Research: SOPP 8201 – Administrative processing of clinical holds for
next generation of biotherapeutics. BioProcess International, March, 2011. investigational new drug applications, Version 4, May 19, 2014.
8. US Food and Drug Administration, Center for Biologics Evaluation and 18. Title 21 Code of Federal Regulations: Tracking from donor to consignee
Research: References for the Regulatory Process for the Office of Cellular, or final disposition, Part 1271.290(e), May 2005.
Tissue and Gene Therapies (OCTGT), February 03, 2015. 19. Title 49 Code of Federal Regulations: Hazardous materials regulations,
9. US Food and Drug Administration: FDA history. <http://www.fda.gov/ Part 171, 2007.
oc/history/> (Date Accessed 4.06.15). 20. Whiteside TL, Griffin DL, Stanson J, et al: Shipping of therapeutic
10. Title 21 Code of Federal Regulations: Part 1271 Human Cells, Tissues, somatic cell products. Cytotherapy 13:201, 2011.
and Cellular and Tissue-Based Products, May 25, 2005. 21. Lindblad RW, Ibenana L, Wagner JE, et al: Cell therapy product
11. US Food and Drug Administration, Center for Biologics Evaluation and administration and safety: data capture and analysis from the Production
Research: About CBER, March 2015. Assistance for Cellular Therapies (PACT) program. Transfusion 55:674,
12. US Food and Drug Administration, Center for Biologics Evaluation 2015.
and Research: Information on submitting an investigational new drug
application, March 2015.